When FIRSTPICK backed Emilė Radytė in 2021, her company Samphire Neuroscience was still building its first product and the risk, by the fund’s own assessment, was high. There was no revenue, no clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results